Skip to main content

Table 4 Mean difference of body fat percentage and cardiometabolic risk factors according to agreement and non-agreement between weight status based on IOTF and CDC, and IOTF and WHO classification systems

From: Overweight and obesity prevalence among Cree youth of Eeyou Istchee according to three body mass index classification systems

  IOTF vs. CDC   
Non-agreement IOTF overweight/ CDC obese (n = 13) Agreement IOTF obese/ CDC obese (n = 123) Mean difference (95% CI) P
Body fat, % 34.5 ± 6.6 41.7 ± 6.7 −7.1 (−11.0, −3.2) <0.001
SBP, mm Hg 104 ± 10.4 108 ± 11.6 −3.5 (−10.2, 3.1) 0.29
DBP, mm Hg 63 ± 8.9 65 ± 11.6 −2.1 (−8.7, 4.4) 0.52
Fasting plasma glucose, mmol/L 5.0 ± 0.40 5.2 ± 0.50 −0.17 (−0.45, 0.12) 0.26
Fasting plasma insulin, pmol/L 142 ± 49 207 ± 135 −65.3 (−102, −28.5) 0.001
HOMA2-IR 2.6 ± 0.86 3.5 ± 2.0 −0.97 (−1.6, −0.36) 0.003
TG, mmol/L 1.1 ± 0.45 1.1 ± 0.61 0.003 (−0.50, 0.51) 0.99
HDL-C, mmol/L 1.2 ± 0.32 1.1 ± 0.28 0.11 (−0.13, 0.35) 0.38
TG/HDL-C ratio 0.97 ± 0.46 1.1 ± 0.72 −0.14 (−0.74, 0.46) 0.64
  IOTF vs. WHO   
Non-agreement IOTF overweight/ WHO obese (n = 19) Agreement IOTF obese/ WHO obese (n = 123) Mean difference (95% CI) P
Body fat, % 33.6 ± 6.5 41.7 ± 6.7 −8.1 (−11.3, −4.8) <0.001
SBP, mm Hg 104 ± 9.3 108 ± 11.6 −4.2 (−9.7, 1.3) 0.13
DBP, mm Hg 63 ± 10.1 65 ± 11.6 −2.2 (−7.7, 3.4) 0.44
Fasting plasma glucose, mmol/L 5.1 ± 0.39 5.2 ± 0.50 −0.12 (−0.36, 0.12) 0.32
Fasting plasma insulin, pmol/L 135 ± 55.3 207 ± 135 −71.9 (−107, −36.6) <0.001
HOMA2-IR 2.5 ± 0.98 3.5 ± 2.0 −1.1 (−1.7, −0.50) <0.001
TG, mmol/L 0.97 ± 0.40 1.1 ± 0.61 −0.18 (−0.55, 0.20) 0.36
HDL-C, mmol/L 1.4 ± 0.35 1.1 ± 0.28 0.23 (0.04, 0.42) 0.02
TG/HDL-C ratio 0.77 ± 0.43 1.1 ± 0.72 −0.34 (−0.78, 0.10) 0.13
  1. Values are presented as arithmetic means ± standard deviations. P values were obtained by t-tests
  2. Information on fasting plasma glucose and insulin was missing for 1 participant, on HOMA2-IR for 3 participants, and on TG, HDL-C and TG/HDL-C ratio for 91 participants
  3. CDC Centers for Disease Control and Prevention; DBP diastolic blood pressure; HDL-C high-density lipoprotein cholesterol; HOMA2-IR homeostatic model assessment 2 for insulin resistance; IOTF International Obesity Task Force; SBP systolic blood pressure; TG triglycerides; WHO World Health Organization